Last reviewed · How we verify
NCT06276309
Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors
trial in Neuroendocrine Neoplasm in 300 participants. Currently enrolling.
30 December 2024
Quick facts
| Lead sponsor | Fujian Maternity and Child Health Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 February 2024 |
| Primary completion | 30 December 2024 |
| Estimated completion | 28 February 2025 |
| Sites | 9 locations across China |
Conditions studied
- Neuroendocrine Neoplasm — all drugs for Neuroendocrine Neoplasm →
- China — all drugs for China →
- Women — all drugs for Women →
- Cervical Cancer — all drugs for Cervical Cancer →
Sponsor
Fujian Maternity and Child Health Hospital
Who can join
Eligibility, female only, with Neuroendocrine Neoplasm or China. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors were collected, including age, preoperative biopsy pathology results, postoperative histopathological results, TCT results, and colposcopy biopsy pathology results. At the same time, paraffin tissue specimens (remaining specimens after pathological diagnosis) from 100 cases of cervical neuroendocrine tumors from multiple centers across the country were collected to establish a cervical neuroendocrine tumor data follow-up database. Protein concentration and omics analysis were performed on the data results, to evaluate the molecular characteristics and prognosis of cervical neuroendocrine tumor proteins, and to preliminarily explore its clinical application value.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06276309
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neuroendocrine Neoplasm
Currently open trials in the same condition.
- NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
- NCT06785597 — EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Neuroendocrine Neoplasms · recruiting
- NCT06732505 — A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens · Phase 1 · recruiting
- NCT06855095 — Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial · Phase 2, PHASE3 · recruiting
- NCT05879055 — A Study of PM8002 in Combination With Chemotherapy in Patients With NEN · Phase 2 · recruiting
Other Fujian Maternity and Child Health Hospital trials
Trials by the same sponsor.
- NCT06137352 — Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity · not yet recruiting
- NCT06204133 — Model Study on Cervical Cancer Screening Strategies and Risk Prediction · completed
- NCT05932563 — Study on the Epidemiological Characteristics of Female HPV Vaccination in China · unknown
- NCT05745597 — Prognostic Study of HPV Virus Integration in Women With HSIL · unknown
- NCT05932576 — A Multicenter Cohort Study Assessing the Efficacy and Adverse Effects of HPV Vaccination in Chinese Women · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06276309 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Maternity and Child Health Hospital
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06276309.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing